MTO1: Potential Drug Target and Biomarker for Various Diseases

Target Name: MTO1

NCBI ID: G25821

MTO1

MTO1: Potential Drug Target and Biomarker for Various Diseases

MTO1 (Mesothelin-Transmembrane Protein 1) is a protein that is expressed in various tissues throughout the body, including the skin, heart, lungs, and brain. It is a member of the mesothelin family, which is a group of transmembrane proteins that are involved in cell-cell and cell-extracellular matrix interactions.

MTO1 is known for its role in cell-cell adhesion and tissue structure. It is expressed in high levels in many types of cancer, including breast, ovarian, and prostate cancer. It has also been shown to be involved in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the key challenges in studying MTO1 is its complex cellular and molecular biology. Despite its widespread expression, understanding its function and how it interacts with other proteins and molecules can be challenging. However, research into MTO1 has made significant progress in recent years, and several potential drug targets and biomarkers have been identified.

One potential drug target for MTO1 is its role in cell-cell adhesion. MTO1 has been shown to be involved in the formation of tight junctions, which are a type of cell-cell adhesion that helps to maintain tissue structure and prevent excessive fluid leakage. MTO1 has also been shown to interact with other proteins that are involved in cell-cell adhesion, including E-cadherin and Z-catenin. Targeting MTO1 with drugs that can modulate its activity in these ways may be a promising strategy for treating certain types of cancer.

Another potential drug target for MTO1 is its role in neurodegenerative diseases. MTO1 has been shown to be involved in the development and progression of various neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. It has also been shown to interact with other proteins that are involved in neurodegeneration, including tau and beta-amyloid. Targeting MTO1 with drugs that can modulate its activity in these ways may be a promising strategy for treating neurodegenerative diseases.

In addition to its potential as a drug target, MTO1 has also been shown to be a potential biomarker for certain types of cancer. Its high expression levels in many types of cancer make it a potentially useful biomarker for these diseases. For example, MTO1 has been shown to be highly expressed in breast cancer, and its levels have been used as a biomarker to predict the effectiveness of certain types of treatments.

Overall, MTO1 is a complex and highly versatile protein that has the potential to be a drug target and biomarker for a variety of diseases. Further research is needed to fully understand its role and how it interacts with other proteins and molecules.

Protein Name: Mitochondrial TRNA Translation Optimization 1

Functions: Involved in the 5-carboxymethylaminomethyl modification (mnm(5)s(2)U34) of the wobble uridine base in mitochondrial tRNAs

The "MTO1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MTO1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets